Palisade Bio, Inc. (PALI)
Develops oral medications targeting the colon to treat inflammatory bowel disease.
$2.00-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+98.5%
The outlook
PALI trades at $2, positioned about two-thirds of the way up from its 52-week low. Analyst consensus is Strong Buy, with an average price target implying significant upside versus the current price. The stock is trading above both its 50- and 200-day moving averages, reflecting a positive near-term trend.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range63% of the way from its 52-week low to high
Price targetAvg target +411% vs current price
Analyst price target
~12-month · 9 analysts$10.22average target+411.1% vs now
Now $2.00
Low $5.00High $25.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$347.6M
52-wk high
$2.86
52-wk low
$0.53
50-day avg
$1.92
200-day avg
$1.92
Trailing P/E
16.7